Novel drug approvals in the United States surpassed even 2014's unprecedented totals. The broad trends are familiar but, as Chris Morrison reports, 2015 had its share of pioneering achievements.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2015. Nat Biotechnol 34, 129–132 (2016). https://doi.org/10.1038/nbt.3472
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3472
- Springer Nature America, Inc.
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Fresh from the biotech pipeline—2016
Nature Biotechnology (2017)